The clinicopathological characteristics with long-term outcomes in malignant mesothelioma

被引:5
|
作者
Dogan, Mutlu [1 ]
Utkan, Gungor [2 ]
Hocazade, Cemil [1 ]
Uncu, Dogan [1 ]
Toptas, Serife [1 ]
Ozdemir, Nuriye [1 ]
Zengin, Nurullah [1 ]
Icli, Fikri [2 ]
机构
[1] Ankara Numune Training & Res Hosp, Dept Med Oncol, TR-06100 Ankara, Turkey
[2] Ankara Univ, Sch Med, Dept Med Oncol, TR-06100 Ankara, Turkey
关键词
Malignant mesothelioma; Mesothelioma; Prognostic factors in mesothelioma; MULTICENTER PHASE-II; PLEURAL MESOTHELIOMA; EXTRAPLEURAL PNEUMONECTOMY; PERITONEAL MESOTHELIOMA; GEMCITABINE; CISPLATIN; CHEMOTHERAPY; CANCER; RADIOTHERAPY; SURVIVAL;
D O I
10.1007/s12032-014-0232-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant mesothelioma (MM) is a neoplasm which originates from serous membranes. It is relatively more common in Turkey. Ninety-nine patients between 2002-2009 were evaluated for survival and patient characteristics with chest pain, dyspnea, weight loss, loss of appetite, anemia, leukocytosis, thrombocytosis and lactate dehydrogenase (LDH) elevation, retrospectively. Male/female ratio was 1.41(58/41). Median age was 53(27-88). Asbestosis exposure rate was 78.5 %. Most of the patients had better ECOG-PS (88.7 % for 1-2). Chest pain (47.7 %), dyspnea (44.8 %), weight loss (49 %), loss of appetite (50 %), anemia (38 %), leukocytosis (37.2 %), thrombocytosis (26.6 %) and LDH elevation (10.1 %) were found with median values such as 11.8 g/dL (5-17.1) for hemoglobin, 8,800/mm(3) for WBC (2,600-38,300), 382,000/mm 3 for platelets (28,000-1,504,000) and 253 IU/L for LDH (85-1,877), respectively. The most common site was pleura (62.3 %). Half of the patients were unclassified, while epitheloid histopathology (39.4 %) was most common in classified ones. RT rate was 42.1 % in operated patients and all had pleural MM. Median OS was 22.9 months. Eighty percent of the patients had first-line CT with a clinical benefit rate of 63.3 %. Second-line CT rate was 29 % with a clinical benefit rate of 44 %. Most preferred CT regimen was cisplatinum and pemetrexed. Most of the patients were male in their 50 s with pleural MM. They had chest pain, dyspnea, weight loss and loss of appetite as the most common symptoms at diagnosis. Only half of the patients could be subtyped with a predominance of epitheloid histology.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [41] Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases
    Butnor, Kelly J.
    Brownlee, Noel A.
    Mahar, Annabelle
    Pavlisko, Elizabeth N.
    Sporn, Thomas A.
    Roggli, Victor L.
    LUNG CANCER, 2016, 95 : 1 - 7
  • [42] Pembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long-term survival: A case report and literature review
    Xue, Chongxiang
    Dong, Zhe
    Tan, Kexin
    Zhang, Xu
    Yu, Yixuan
    Wang, Shuo
    Zheng, Jiabin
    Cui, Huijuan
    ONCOLOGY LETTERS, 2025, 29 (04)
  • [43] Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast
    Spanheimer, Philip M.
    Murray, Melissa P.
    Zabor, Emily C.
    Stempel, Michelle
    Morrow, Monica
    Van Zee, Kimberly J.
    Barrio, Andrea V.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (07) : 2136 - 2143
  • [44] Duodenal gastrointestinal stromal tumors: clinicopathological characteristics, surgery, and long-term outcome
    Shen, Chaoyong
    Chen, Haining
    Yin, Yuan
    Chen, Jiaju
    Han, Luyin
    Zhang, Bo
    Chen, Zhixin
    Chen, Jiaping
    BMC SURGERY, 2015, 15
  • [45] Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
    Remon, J.
    Nadal, E.
    Domine, M.
    Ruffinelli, J.
    Garcia, Y.
    Pardo, J. C.
    Lopez, R.
    Cilleruelo, A.
    Garcia-Campelo, R.
    Martin, P.
    Juan, O.
    Gonzalez-Larriba, J. L.
    Provencio, M.
    Olmedo, E.
    Ponce, S.
    Cumplido, D.
    Barenys, C.
    Majem, M.
    Massutti, B.
    Rodriguez-Abreu, D.
    Porta, R.
    Sala, M. A.
    Martinez-Kareaga, M.
    Lianes, P.
    Reguart, N.
    LUNG CANCER, 2020, 147 : 83 - 90
  • [46] Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy
    Christian Thieke
    Nils H. Nicolay
    Florian Sterzing
    Hans Hoffmann
    Falk Roeder
    Seyer Safi
    Juergen Debus
    Peter E. Huber
    Radiation Oncology, 10
  • [47] Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival
    Sugarbaker, P. H.
    Chang, D.
    EJSO, 2017, 43 (07): : 1228 - 1235
  • [48] Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma
    Alexander, H. Richard, Jr.
    Bartlett, David L.
    Pingpank, James F.
    Libutti, Steven K.
    Royal, Richard
    Hughes, Marybeth S.
    Holtzman, Matthew
    Hanna, Nader
    Turner, Keli
    Beresneva, Tatiana
    Zhu, Yue
    SURGERY, 2013, 153 (06) : 779 - 786
  • [49] Characteristics of Malignant Pleural Mesothelioma in Women
    Wolf, Andrea S.
    Richards, William G.
    Tilleman, Tamara R.
    Chirieac, Lucian
    Hurwitz, Shelley
    Bueno, Raphael
    Sugarbaker, David J.
    ANNALS OF THORACIC SURGERY, 2010, 90 (03) : 949 - 956
  • [50] Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma
    Muruganandan, Sanjeevan
    Alfonso, Helman
    Franklin, Peter
    Shilkin, Keith
    Segal, Amanda
    Olsen, Nola
    Reid, Alison
    de Klerk, Nick
    Musk, A. W.
    Brims, Fraser
    BRITISH JOURNAL OF CANCER, 2017, 116 (06) : 703 - 708